BioPharma Terug naar discussie overzicht

Genmab, de Deense parel

1. [verwijderd] 23 juni 2011 00:25

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   winkel moet zijn Winkel
   
   
2. sheriff Grover 23 juni 2011 11:35

   auteur info

   • sheriff Grover

     Lid sinds: 18 aug 2010

     Laatste bezoek: 05 mei 2024

   • Aanbevelingen

     Ontvangen: 266

     Gegeven: 34

   •    Aantal posts: 849

   En het grote graaien gaat maar door .... we staan op 39 DKR en de heren hebben zich gewoon weer beloond met tig aantal warrants ... ze zouden zich kapot moeten schamen !! Maar ja 1 geluk als ze net zo goed presteren als ze de laatste 5 jaar hebben gedaan worden die in ieder geval niks waard.. Niks maar dan ook niks hebben ze gepresteerd ja het bedrijf de vernieling in geholpen .
   Nou nog een weekje tot de zaluovereenkomst gesloten kan worden en zo niet geen probleem volgens van de Winkel " we hebben veel betere en snellere alternatieven " heb ik zo iets van goh was het niet verstandiger geweest daar maar mee te beginnen ipv anderhalfjaar met zogenaamde "partners" te praten ????
3. [verwijderd] 23 juni 2011 18:08

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   vd Winkel is een bluffer, dat heeft ie inmiddels wel bewezen.
   Die fabriek in America zouden ze eind vorig jaar ook nog wel verkopen,zij het met een mega verlies in een jaar of anderhalf?. Ik kan me niet aan de indruk onttrekken dat er bij aankoop hiervan ook enige mensen giga veel beter geworden zijn. De belegger natuurlijk niet, die is er om de rekening te betalen.
4. sheriff Grover 23 juni 2011 19:46

   auteur info

   • sheriff Grover

     Lid sinds: 18 aug 2010

     Laatste bezoek: 05 mei 2024

   • Aanbevelingen

     Ontvangen: 266

     Gegeven: 34

   •    Aantal posts: 849

   Ja ook een knap staaltje die plant .....dat gaat echt minimaal $150 tot $175 miljoen kosten !!! Zou mij niet verbazen als er inderdaad iemand $10 miljoen op een buitenlands rekeningetje gestort heeft gekregen ik weet het : het valt niet te bewijzen en dus mogen we het niet zeggen maar denken wel !! Maar wat nog het meest schrijnende , pathetische , angstaanjagende of noem maar op aan dit aandeel is dat er zelfs op deze koers nog niet 1 partij is die een bod doet ......... nog steeds te duur waarschijnlijk...........
5. [verwijderd] 23 juni 2011 21:16

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Volgens mij is het bedrijf met alle toekomstige royalties en de huidige cashpositie een stuk meer waard dan de beurswaarde nu. En dan heb ik het nog niet eens over de pipeline. Op deze koers een lot zonder nieten.
6. sheriff Grover 24 juni 2011 09:28

   auteur info

   • sheriff Grover

     Lid sinds: 18 aug 2010

     Laatste bezoek: 05 mei 2024

   • Aanbevelingen

     Ontvangen: 266

     Gegeven: 34

   •    Aantal posts: 849

   @ Yelolow frog kzou ff wachten als ik jou was zouden er zomaar een paar tussen kunnen zitten .... we hebben ZALU nieuws !!!
   
   Genmab A/S: Genmab Announces Zalutumumab Update
   - Genmab will wind down the zalutumumab program - No impact on 2011 financial guidance - Zalutumumab will be made available for future partnering
   
   Copenhagen, Denmark; June 24, 2011 - Genmab A/S (OMX: GEN) announced today it will wind down the zalutumumab clinical program.
   
   After an extensive search during the first half of the year, the company has not found a satisfactory partnership to take zalutumumab forward in the current climate. As part of the company's disciplined approach and commitment to controlling costs, Genmab will wind down the zalutumumab program. Genmab will continue to pursue partnership leads, but will not invest further in the development of zalutumumab. Cost savings from the wind down will mostly be realized from 2012 and therefore the 2011 financial guidance will not be impacted.
   
   "We have always been focused to ending investment in zalutumumab so that we can concentrate our resources to progress other higher value programs in our pipeline. The product has shown good results in our clinical studies without any serious adverse effects and I believe it has a therapeutic potential; however, we were committed to taking a decision on the future of the product by the end of June and therefore we will now shelve zalutumumab but make it available for partnership should the opportunity arise at some point in the future." said Dr. Jan van de Winkel, CEO of Genmab.
   
   About Genmab A/S Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, Arzerra® (ofatumumab), was approved to treat refractory chronic lymphocytic leukemia after less than eight years in development. Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
   
   
7. h980577. 9 augustus 2011 18:24

   auteur info

   • h980577.

     Lid sinds: 23 mrt 2003

     Laatste bezoek: 05 mei 2024

   • Aanbevelingen

     Ontvangen: 123

     Gegeven: 68

   •    Aantal posts: 2.540

   Iemand enig idee waarom deze vandaag met 30% stijgt?
   Heeft Dhr vd Winkel gisteren iets bijzonders gezegd tijdens Q&A sessie soms?
   Cijfers en uitkomst van een onderzoek waren al van eerder deze maand....
   
   
8. sheriff Grover 9 augustus 2011 20:26

   auteur info

   • sheriff Grover

     Lid sinds: 18 aug 2010

     Laatste bezoek: 05 mei 2024

   • Aanbevelingen

     Ontvangen: 266

     Gegeven: 34

   •    Aantal posts: 849

   h980577 ,zou er niet teveel achter zoeken ,laten we wel zijn het gebeurt op 35 DKR zowat een alltime low . Waarschijnlijk beleggers die hun gemiddelde naar beneden willen brengen en zodoende een sleutel naar de uitgang proberen te vinden ....
9. h980577. 9 augustus 2011 20:40

   auteur info

   • h980577.

     Lid sinds: 23 mrt 2003

     Laatste bezoek: 05 mei 2024

   • Aanbevelingen

     Ontvangen: 123

     Gegeven: 68

   •    Aantal posts: 2.540

   precies wat ik ook zoek, maar nog iets meer stijging maakt uitstappen wel minder pijnlijk :)
10. smith&jones 9 augustus 2011 20:46

    auteur info

    • smith&jones

      Lid sinds: 24 feb 2003

      Laatste bezoek: 06 nov 2023

    • Aanbevelingen

      Ontvangen: 1321

      Gegeven: 1129

    •    Aantal posts: 8.084

    Nah hier moet iets aan de hand zijn, zo'n hevige koersreactie is er niet zomaar...
    
    S&J.
11. sheriff Grover 9 augustus 2011 20:55

    auteur info

    • sheriff Grover

      Lid sinds: 18 aug 2010

      Laatste bezoek: 05 mei 2024

    • Aanbevelingen

      Ontvangen: 266

      Gegeven: 34

    •    Aantal posts: 849

    Ik begin er niet meer aan ! heb het laatste bijgekocht op 83DKR maar hier is geen houden aan....ik zit geloof ik nog op 180 of zo ;0) Zeldzaam hoe ze dit hebben verprutst......
12. h980577. 9 augustus 2011 22:07

    auteur info

    • h980577.

      Lid sinds: 23 mrt 2003

      Laatste bezoek: 05 mei 2024

    • Aanbevelingen

      Ontvangen: 123

      Gegeven: 68

    •    Aantal posts: 2.540

    Hier 55 gemiddeld nu, maar was van narigheid na uitgestopte sprinters naar aandelen gegaan. Verre van een succes dit....
    
    Bij 82 zullen ze er al uit zijn.
    Hoop uiteraard voor jou dat dit begin van lange stijging wordt.
13. sheriff Grover 27 september 2011 09:59

    auteur info

    • sheriff Grover

      Lid sinds: 18 aug 2010

      Laatste bezoek: 05 mei 2024

    • Aanbevelingen

      Ontvangen: 266

      Gegeven: 34

    •    Aantal posts: 849

    De Marketcap van Genmab is nu net zoveel als het bedrag wat ze betaald hebben voor de plant in the US > $ 250 miljoen ......... vraag me af hoe lang ze zo nog aan willen c.q. kunnen modderen .Iemand een idee ?? want vanuit het bedrijf is het zoals gewoonlijk (buiten de medelingen van toekenning van warrants aan management en het bezoeken van investor conferences !!(welk nut die hebben als we naar de koers kijken ;o)oorverdovend stil.
    Wijma schat ze nog steeds DKR 104 waard , zie link klikken op cover magazine pagina 9/tm 12 . www.lifesciencestribune.com/
    
    sheriff Grover
14. sheriff Grover 25 oktober 2011 15:53

    auteur info

    • sheriff Grover

      Lid sinds: 18 aug 2010

      Laatste bezoek: 05 mei 2024

    • Aanbevelingen

      Ontvangen: 266

      Gegeven: 34

    •    Aantal posts: 849

    Lonza enters into Genmab A/S to develop antibody drug conjugate
    
    Written by The Edge
    Tuesday, 25 October 2011 20:29
    
    Lonza has agreed to develop and manufacture an antibody drug conjugate (ADC), HuMax-TF with Genmab A/S.
    
    TF or tissue factor is a protein involved in tumour signalling and angiogenesis that is highly expressed on solid tumours. The use of ADCs as therapeutic agents is becoming an important therapeutic approach for the treatment of various cancers.
    
    The project will use Lonza’s experts in both antibody production and drug conjugation for Genmab’s technology.
    
    Lonza will initiate process development and cGMP manufacturing for Genmab’s monoclonal antibody HuMax-TF in its Slough, UK facility
    
15. sheriff Grover 17 november 2011 09:59

    auteur info

    • sheriff Grover

      Lid sinds: 18 aug 2010

      Laatste bezoek: 05 mei 2024

    • Aanbevelingen

      Ontvangen: 266

      Gegeven: 34

    •    Aantal posts: 849

    Genmab A/S: Genmab Announces US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit
    - US Court enters judgment that Arzerra does not infringe Genentech and Biogen Idec US patent covering methods of treating CLL with anti-CD20 antibodies
    
    Copenhagen, Denmark; November 17, 2011 - Genmab A/S (OMX: GEN) announced today that a US District Court entered final judgment in favour of GlaxoSmithKline (GSK) in a patent infringement case involving Arzerra brought against GSK by Genentech and Biogen Idec.
    
    Genentech and Biogen Idec filed the patent infringement lawsuit in Q1 2010 with the US District Court in San Diego, California claiming Arzerra infringed US Patent No 7,682,612 covering methods of treating Chronic Lymphocytic Leukemia (CLL) with anti-CD20 antibodies. GSK denied infringement and claimed the patent was invalid and unenforceable.
    
    The decision in favour of GSK came after the court defined certain terms of the patent claims. Based on this Genentech and Biogen Idec conceded to a judgment in favour of GSK's counterclaim of non-infringement. Genentech and Biogen Idec will have the option to appeal the decision concerning the interpretation of the patent claims.
    
    Arzerra, Genmab's anti-CD20 antibody, is partnered with GSK and marketed in the US and Europe for the treatment of fludarabine and alemtuzumab refractory CLL.
    
    
16. [verwijderd] 16 juli 2012 17:24

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    Genmab Enters Broad Collaboration with Janssen Biotech, Inc. for DuoBody Platform
    
    Company Announcement
    •Genmab enters DuoBody™ technology collaboration
    •$3.5 million upfront payment to Genmab
    
    Copenhagen, Denmark; July 12, 2012 — Genmab A/S (OMX: GEN) announced today it has entered into a collaboration with Janssen Biotech, Inc. and its affiliates ("Janssen") to create and develop bispecific antibodies using its DuoBody technology platform. Genmab will create panels of bispecific antibodies to multiple disease target combinations identified by Janssen, who will in turn fully fund research at Genmab.
    
    Under the terms of the agreement, Genmab and Janssen will collaborate on the research of up to 10 DuoBody programs and Genmab will receive an upfront payment of $3.5 million (DKK 21 million) from Janssen and all research by Genmab will be fully funded by Janssen. In addition, Genmab will potentially be entitled to milestone and license payments of up to approximately $175 million (DKK 1,062 million) for each product as well as royalties on any commercialized products.
    
    "Since the introduction of our DuoBody platform in 2010, we have believed in its potential to become the preferred technology for next generation bispecific antibody therapeutics. Today's announcement is another indicator that the pharmaceutical industry recognizes our leadership in the therapeutic antibody field," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "We very much look forward to working with Janssen in creating trend-setting bispecific antibody treatments."
    
    This agreement is not expected to have a material impact on Genmab's 2012 financial guidance.
    
    About the DuoBody Platform
    The DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies' specificity and efficacy in inactivating the disease targets. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale.
    
    ir.genmab.com/releasedetail.cfm?Relea...
17. [verwijderd] 27 juli 2012 18:34

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Arzerra Second Quarter 2012 Net Sales Figures
    
    View Arzerra sales information as reported in GlaxoSmithKline's Second Quarter 2012 Results
    
    Company Announcement
    •Arzerra worldwide net sales in Q2 2012 totaled GBP 14.9 million
    •Genmab expects royalty payment of DKK 27 million
    
    Copenhagen, Denmark; July 25, 2012 — Genmab A/S (OMX: GEN) announced today that the Arzerra (ofatumumab) net sales during the second quarter of 2012 were GBP 14.9 million (approximately DKK 137 million). This figure consists of net sales in the U.S. of GBP 9.4 million and in the rest of the world of GBP 5.5 million. Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK 27 million.
    
    The rest of world sales for the second quarter were enhanced by sales related to the supply of ofatumumab for clinical trials run by other companies.
    
    The conversion from GBP to DKK has been made using the Danish Central Bank average rates for the second quarter of 2012 (GBP 1.00 = DKK 9.1742).
    
    ir.genmab.com/releasedetail.cfm?Relea...
18. [verwijderd] 16 augustus 2012 19:13

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    Genmab Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance
    
    August 15, 2012; Copenhagen, Denmark;
    Interim Report for the First Half 2012
    •DuoBody™ collaborations signed with Novartis and Janssen Biotech
    •Daratumumab preliminary safety and efficacy data presented at ASCO and EHA
    •Arzerra® first half net sales increased 37% over prior year
    •2012 guidance improved and H1 operating result and cash burn improved by 36% over 2011
    
    "During the second quarter we were pleased to see further increases in Arzerra sales, promising early data from our daratumumab program presented at two prestigious cancer conferences and improvements in our operating result, cash burn and full year guidance. The highlight for the quarter though, was the signing of two DuoBody agreements with Novartis and Janssen Biotech which are potentially worth over USD 1.9 billion in milestone payments. These deals further validate the value and potential of our bispecific technology platform. We are delighted to see our strategy evolving into tangible results," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
    
    Financial Performance First Half
    •Genmab's revenues were DKK 206 million for the first half of 2012 compared to DKK 167 million for the corresponding period in 2011. The increase of DKK 39 million or 23% was mainly driven by higher Arzerra royalties and the achievement of a milestone under our collaboration with GlaxoSmithKline (GSK).
    •Operating expenses decreased 2% from DKK 294 million in the first half of 2011 to DKK 287 million in the first half of 2012.
    •An operating loss of DKK 82 million in the first half of 2012 compared to DKK 127 million in the corresponding period for 2011, an improvement of 36%. The improved operating result was driven by increased revenues, and continued strong focus on cost control.
    •On June 30, 2012, Genmab had a cash position of DKK 952 million resulting in a cash burn of DKK 153 million in the first half of 2012. This was a reduction of DKK 85 million or 36% compared to the corresponding period in 2011.
    
    Business Progress Second Quarter to Present
    •April: GSK submitted a New Drug Application (NDA) for ofatumumab to regulatory authorities in Japan for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior treatment. This filing triggered a milestone payment of DKK 20 million in May.
    •May/June: Preliminary safety and efficacy data from the daratumumab Phase I/II study in multiple myeloma were presented at the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) meetings.
    •June: Genmab entered a DuoBody technology collaboration with Novartis to create and develop bispecific antibodies. Genmab received an upfront payment of USD 2 million, and the total potential value of the agreement would be approximately USD 175 million, if all milestones are met, plus research funding and royalties.
    •July: Genmab entered into a collaboration with Janssen Biotech to create and develop bispecific antibodies for up to 10 programs using its DuoBody technology platform. Genmab received an upfront payment of USD 3.5 million. Genmab will potentially be entitled to milestone and license payments of up to approximately USD 175 million per program, if all milestones are met, plus research funding and royalties.
    •July: GSK reported net sales for Arzerra for the second quarter of 2012 of GBP 14.9 million, an increase of 42% over Q2 2011, resulting in royalty income of DKK 27 million to Genmab.
    
    Outlook
    Genmab is improving its 2012 financial guidance. The revenue and operating result are improved and cash burn is reduced, mainly as a result of the inclusion of income from DuoBody collaborations.
    
    Conference Call
    Genmab will hold a conference call in English to discuss the results for the first half of 2012 today, Wednesday, August 15, at 6.00 pm CEST, 5.00 pm BST or noon EDT. The dial in numbers are:
    
    +1 718 354 1226 (US participants) and ask for the Genmab conference call
    +44 207 509 5139 (international participants) and ask for the Genmab conference call
    
    A live and archived webcast of the call and relevant slides will be available at www.genmab.com.
    
    To read the full PDF version of the Interim Report for the First Half 2012, visit Genmab's website at ir.genmab.com/annuals.cfm.
    
    ir.genmab.com/releasedetail.cfm?Relea...
19. sheriff Grover 30 augustus 2012 11:13

    auteur info

    • sheriff Grover

      Lid sinds: 18 aug 2010

      Laatste bezoek: 05 mei 2024

    • Aanbevelingen

      Ontvangen: 266

      Gegeven: 34

    •    Aantal posts: 849

    Genmab A/S: Genmab Enters Worldwide Agreement with Janssen for Daratumumab
    Company Announcement
    
    - Genmab licenses daratumumab to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson - $55 million upfront payment to Genmab - Johnson & Johnson Development Corporation invests DKK 475 million (approx. $80 million) in new Genmab shares - Total potential agreement value including upfront payment, equity investment and milestones in excess of $1.1 billion
    
    Copenhagen, Denmark; August 30, 2012 - Genmab A/S (OMX: GEN) announced today a global license and development agreement for daratumumab (HuMax®-CD38), a human CD38 monoclonal antibody with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). Daratumumab is currently in development for multiple myeloma and may have potential in other cancer indications such as acute myeloid leukemia. Under the terms of the agreement, Genmab will grant Janssen an exclusive worldwide license to develop and commercialize daratumumab as well as a backup human CD38 antibody.
    
    Under the terms of the agreement, Genmab will receive an upfront license fee of $55 million (approximately DKK 327 million) and Johnson & Johnson Development Corporation (JJDC) will invest DKK 475 million, (approximately $80 million) to subscribe for 5.4 million new shares of Genmab at a price of DKK 88 per share. Genmab's closing share price on August 29, 2012 was DKK 67.85. Genmab could also be entitled to up to $1 billion in development, regulatory and sales milestones, in addition to tiered double digit royalties. Janssen will be fully responsible for all costs associated with developing and commercializing daratumumab going forward, including the costs of two ongoing Phase I/II studies.
    
    "Janssen was one of the first companies to recognize the power and promise of monoclonal antibodies and today is a world leader in biologics; we look forward to applying that same expertise to daratumumab to help meet the needs of patients with multiple myeloma," said William N. Hait, M.D., Ph.D., Head of Janssen Research & Development, LLC. "Daratumumab is an exciting, innovative compound, and we are delighted to add it to our portfolio."
    
    "We are very pleased to partner with Janssen on another Genmab innovation and look forward to working with them to accelerate the development of daratumumab and to maximize the value of this product," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "This agreement significantly strengthens our financial position, ensuring that Genmab can continue to develop much needed differentiated antibody therapeutics to help cancer patients in the future."
    
    The transaction is subject to customary closing conditions, including approval of a prospectus by the Danish Financial Supervisory Authority and clearance by the US antitrust authorities under the Hart-Scott-Rodino Act, and will become final as soon as these conditions have been met.
    
    
20. sheriff Grover 30 augustus 2012 11:14

    auteur info

    • sheriff Grover

      Lid sinds: 18 aug 2010

      Laatste bezoek: 05 mei 2024

    • Aanbevelingen

      Ontvangen: 266

      Gegeven: 34

    •    Aantal posts: 849

    OUTLOOK
    
    -------------------------------------------------------------------------------- MDKK Revised Guidance** Previous Guidance August 30, 2012 August 15, 2012 -------------------------------------------------------------------------------- Revenue 435 - 460 375 - 400 Operating expenses (600) - (625) (600) - (625) Operating loss continuing operations (140) - (190) (200) - (250) Discontinued operation (40) (40) Cash position beginning of year* 1,105 1,105 Cash used in operations (375) - (400) (375) - (400) Cash from license agreement & 800 - share subscription agreement Cash position at end of year* excl. MN 1,505 - 1,530 705 - 730 sale Facility sale 320 320 Cash position at end of year* 1,825 - 1,850 1,025 - 1,050 -------------------------------------------------------------------------------- *Cash, cash equivalents, and marketable securities **Dependent on closing of the transaction with Janssen and JJDC -------------------------------------------------------------------------------- -
    
    Continuing Operations We expect our 2012 revenue to now be in the range of DKK 435 - 460 million, an improvement of DKK 60 million from the previous DKK 375 - 400 million. The increased revenue is primarily due to the daratumumab license agreement and share subscription agreement entered into with Janssen and JJDC, respectively. The agreements include reimbursement of certain research and development costs and the amortization of the upfront payment and a part of the share premium which initially is recognized as deferred income and allocated as revenue over a number of years.
    
    Our revenue consists primarily of non-cash amortization of deferred revenue totaling DKK 250 million (previous guidance was DKK 230 million) and royalties on sales of Arzerra, which still are expected to be in the range of DKK 90 - 100 million.
    
    We anticipate that our 2012 operating expenses from continuing operations will remain the same as the previous guidance at DKK 600 - 625 million.
    
    With the increase in revenue and no change to the operating expense guidance, the operating loss also improves. We expect the operating loss from continuing operations for 2012 to be approximately DKK 140 - 190 million, an improvement of DKK 60 million over the previous guidance of DKK 200 - 250 million.
    
    Discontinued Operation The discontinued operation guidance of DKK 40 million relates to the ongoing running costs of maintaining the Minnesota manufacturing facility in a validated state and represents a full 12 months of activity. This expense could be lower if the facility is sold before the end of the year.
    
    The fair value of the facility less cost to sell is currently estimated to be USD 58 million, approximately DKK 320 million at an assumed exchange rate of USD 1.00 = DKK 5.50. As of August 29, 2012, the exchange rate between USD and DKK was 5.9388. We remain focused on entering a sales agreement and anticipate the sale of the facility in 2012.
    
    Cash Position As of December 31, 2011, we had a cash position of DKK 1,105 million and are still projecting a cash burn from operations in 2012 of DKK 375 - 400 million as the reimbursement of certain research and development costs under the daratumumab license agreement will be received in early 2013.
    
    We are now projecting a cash position at the end of 2012, excluding the facility sale, of DKK 1,505 - 1,530 million, an increase of DKK 800 million compared to the previous guidance of DKK 705 - 730 million. The improvement is due to the equity investment and upfront payment related to the daratumumab license agreement and share subscription agreement. Taking into account the planned sale of the facility, the projected cash position at the end of 2012 would increase by DKK 320 million to DKK 1,825 - 1,850 million, compared to the previous guidance of DKK 1,025 - 1,050 million.
    
    In addition to factors already mentioned, the estimates above are subject to change for numerous reasons, including but not limited to, closing of the transaction with Janssen and JJDC, the timing and variation of development activities (including activities carried out by our collaboration partners) and related income and costs; the successful completion of the manufacturing facility sale; fluctuations in the value of our marketable securities; Arzerra sales and corresponding royalties to Genmab; and currency exchange rates. The financial guidance also assumes that no significant new agreements are entered into during 2012 that could materially affect the results.